Related Experiment Videos
Inhibitors of sickling
The American Journal of Pediatric Hematology/Oncology
|January 1, 1982
Summary
Researchers are developing new sickle cell anemia therapies targeting hemoglobin S. While many agents show promise in lab tests, safe and effective treatments are still under investigation, offering hope for the future.
Area of Science:
- Hematology
- Molecular Biology
- Pharmacology
Background:
- Sickle cell anemia is characterized by the sickling of red blood cells due to abnormal hemoglobin S.
- Existing in vitro antisickling agents often lack specificity, affecting other cellular components.
- Developing targeted therapies for hemoglobin S is crucial for effective treatment.
Purpose of the Study:
- To review the landscape of antisickling agents and their mechanisms of action.
- To highlight the rational design of specific hemoglobin S inhibitors.
- To assess the potential of novel therapeutic strategies for sickle cell anemia.
Main Methods:
- Review of scientific literature on antisickling agents.
- Analysis of mechanisms targeting hemoglobin S polymerization and oxygen affinity.
- Evaluation of in vitro and in vivo efficacy of therapeutic candidates.
Main Results:
- Numerous agents inhibit sickling in vitro by interacting with hemoglobin S.
- Novel agents, like specific bifunctional aspirin derivatives, show increased hemoglobin specificity.
- Membrane-active agents and methods to reduce intracellular hemoglobin S concentration are also explored.
Conclusions:
- Current antisickling therapies lack proven in vivo safety and efficacy.
- Rational drug design focusing on hemoglobin S offers a promising therapeutic avenue.
- Ongoing research into diverse antisickling agents provides optimism for future sickle cell anemia treatments.